TransCode Therapeutics (NASDAQ:RNAZ) will execute its previously announced 1-for-33 reverse stock split on Dec. 4, 2024. The company’s common stock is expected to begin trading on a split ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC ...

According to Benzinga Pro, TransCode Therapeutics's peer group average for short interest as a percentage of float is 3.92%, ...

Shares of TransCode Therapeutics stock opened at $3.85 on Wednesday. The business has a fifty day simple moving average of $395.55 and a 200-day simple moving average of $565.72. TransCode ...

Transcode Therapeutics shares are trading lower by 11% to 34 cents Monday afternoon. The company announced its Board's approval of a 1-for-33 reverse stock split. What Else: Approved by ...

Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on TransCode Therapeutics (RNAZ – Research Report) and keeping the price target at $3.00. Emily Bodnar has given her Buy rating ...

TransCode Therapeutics (RNAZ) announced that the Safety Review Committee, or SRC, monitoring its Phase 1 clinical trial has unanimously approved opening of the third cohort of patients based on ...

TransCode Therapeutics (RNAZ) has entered into a securities purchase agreement with certain institutional investors. The aggregate gross cash proceeds are expected to be approximately $8M before ...

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today ...

BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to ...

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating ...